-
www.qualitymeasures.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-170-fullreport.pdf
April 01, 2016 - Measure Description
Please provide a non-technical description of the measure that conveys what it measures … Population – infants (29 days to 1 year) (specify age range): No.
q. … Population – pre-school age children (1 year through 5 years) (specify age range):
No.
r. … During the 1990s, the diabetes rate increased by an average of 3 percent
per year, but between 2000 … and 2002, the pace of increase rose to 6 percent per year (American
Dietetic Association, 2008).
-
www.innovations.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-170-fullreport.pdf
April 01, 2016 - Measure Description
Please provide a non-technical description of the measure that conveys what it measures … Population – infants (29 days to 1 year) (specify age range): No.
q. … Population – pre-school age children (1 year through 5 years) (specify age range):
No.
r. … During the 1990s, the diabetes rate increased by an average of 3 percent
per year, but between 2000 … and 2002, the pace of increase rose to 6 percent per year (American
Dietetic Association, 2008).
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-170-fullreport.pdf
April 01, 2016 - Measure Description
Please provide a non-technical description of the measure that conveys what it measures … Population – infants (29 days to 1 year) (specify age range): No.
q. … Population – pre-school age children (1 year through 5 years) (specify age range):
No.
r. … During the 1990s, the diabetes rate increased by an average of 3 percent
per year, but between 2000 … and 2002, the pace of increase rose to 6 percent per year (American
Dietetic Association, 2008).
-
www.cahps.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-170-fullreport.pdf
April 01, 2016 - Measure Description
Please provide a non-technical description of the measure that conveys what it measures … Population – infants (29 days to 1 year) (specify age range): No.
q. … Population – pre-school age children (1 year through 5 years) (specify age range):
No.
r. … During the 1990s, the diabetes rate increased by an average of 3 percent
per year, but between 2000 … and 2002, the pace of increase rose to 6 percent per year (American
Dietetic Association, 2008).
-
www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-170-fullreport.pdf
April 01, 2016 - Measure Description
Please provide a non-technical description of the measure that conveys what it measures … Population – infants (29 days to 1 year) (specify age range): No.
q. … Population – pre-school age children (1 year through 5 years) (specify age range):
No.
r. … During the 1990s, the diabetes rate increased by an average of 3 percent
per year, but between 2000 … and 2002, the pace of increase rose to 6 percent per year (American
Dietetic Association, 2008).
-
www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-170-fullreport.pdf
April 01, 2016 - Measure Description
Please provide a non-technical description of the measure that conveys what it measures … Population – infants (29 days to 1 year) (specify age range): No.
q. … Population – pre-school age children (1 year through 5 years) (specify age range):
No.
r. … During the 1990s, the diabetes rate increased by an average of 3 percent
per year, but between 2000 … and 2002, the pace of increase rose to 6 percent per year (American
Dietetic Association, 2008).
-
ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-170-fullreport.pdf
April 01, 2016 - Measure Description
Please provide a non-technical description of the measure that conveys what it measures … Population – infants (29 days to 1 year) (specify age range): No.
q. … Population – pre-school age children (1 year through 5 years) (specify age range):
No.
r. … During the 1990s, the diabetes rate increased by an average of 3 percent
per year, but between 2000 … and 2002, the pace of increase rose to 6 percent per year (American
Dietetic Association, 2008).
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-193-disposition-comments-naloxone.pdf
November 27, 2017 - There is a
need to account for the fact that the drugs available
on the street tend to vary from year … to year and
have recently focused on high potency, inexpensive
synthetic opioids and thus data from … Healthcare Research and Quality (AHRQ),
Rockville, MD, with the finding and views being
that of the author … & Affiliation Section Comment Response
Public
Reviewer #1,
Joi Kelly
General
Comments
The author … This includes description of
the same results in various discussion sections
provided.
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-193-disposition-comments-naloxone.pdf
November 27, 2017 - There is a
need to account for the fact that the drugs available
on the street tend to vary from year … to year and
have recently focused on high potency, inexpensive
synthetic opioids and thus data from … Healthcare Research and Quality (AHRQ),
Rockville, MD, with the finding and views being
that of the author … & Affiliation Section Comment Response
Public
Reviewer #1,
Joi Kelly
General
Comments
The author … This includes description of
the same results in various discussion sections
provided.
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/h-w99jVsodSL33kV2h2_qW
April 17, 2018 - Author Audio Interview
Related article
Author/Group Information: The US
Preventive Services Task Force … Corresponding Author: David C. … USPSTF Levels of Certainty Regarding Net Benefit
Level of Certainty Description
High
The available … risk
assessment with multicomponent interventions in older adults
who have had 2 falls in the past year … Author Contributions: Dr Grossman had full access
to all of the data in the study and takes
responsibility
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/migraine-future_research.pdf
April 01, 2013 - The findings and conclusions in this document are those
of the author(s), who are responsible for its … Considerations Interrupted Time Series (Without a Comparison Group)
Design Description A cohort of … Considerations RCT
Design Description
Individual patients randomly assigned to either multimodal … Considerations RCT
Design Description
Individual patients randomly assigned to either combination … Cephalalgia. 2007
May;27(5):469; author reply -70. PMID:
17448186.
18. U.S.
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/migraine-future_research.pdf
April 01, 2013 - The findings and conclusions in this document are those
of the author(s), who are responsible for its … Considerations Interrupted Time Series (Without a Comparison Group)
Design Description A cohort of … Considerations RCT
Design Description
Individual patients randomly assigned to either multimodal … Considerations RCT
Design Description
Individual patients randomly assigned to either combination … Cephalalgia. 2007
May;27(5):469; author reply -70. PMID:
17448186.
18. U.S.
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/_ZPNC3vqdS3R-ggXro6UAM
April 05, 2016 - (D recommendation)
JAMA. 2016;315(13):1372-1377. doi:10.1001/jama.2016.2638
Editorial page 1343
Author … Corresponding Author: Albert L. Siu,
MD, MSPH (chair@uspstf.net). … USPSTF Levels of Certainty Regarding Net Benefit
Level of Certainty Description
High
The available … emergency
department visits.4 Health care costs associated with COPD are
an estimated $32 billion per year … However, rates of COPD
exacerbation were extremely low at baseline (<1 episode per year),
even among
-
www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-229-fullreport.pdf
February 01, 2018 - Measure Description
Please provide a non-technical description of the measure that conveys what it measures … The results of a 9-year
retrospective study (Han, et al., 2003) indicated that 29 percent of infants … Population – infants (29 days to 1 year) (specify age range): Yes; ages 29 days to 1
year.
q. … Research Evidence
Research evidence should include a brief description of the evidence base for valid … Include results of all tests of validity and reliability, including description(s) of the study
sample
-
www.qualitymeasures.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-229-fullreport.pdf
February 01, 2018 - Measure Description
Please provide a non-technical description of the measure that conveys what it measures … The results of a 9-year
retrospective study (Han, et al., 2003) indicated that 29 percent of infants … Population – infants (29 days to 1 year) (specify age range): Yes; ages 29 days to 1
year.
q. … Research Evidence
Research evidence should include a brief description of the evidence base for valid … Include results of all tests of validity and reliability, including description(s) of the study
sample
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-229-fullreport.pdf
February 01, 2018 - Measure Description
Please provide a non-technical description of the measure that conveys what it measures … The results of a 9-year
retrospective study (Han, et al., 2003) indicated that 29 percent of infants … Population – infants (29 days to 1 year) (specify age range): Yes; ages 29 days to 1
year.
q. … Research Evidence
Research evidence should include a brief description of the evidence base for valid … Include results of all tests of validity and reliability, including description(s) of the study
sample
-
www.innovations.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-229-fullreport.pdf
February 01, 2018 - Measure Description
Please provide a non-technical description of the measure that conveys what it measures … The results of a 9-year
retrospective study (Han, et al., 2003) indicated that 29 percent of infants … Population – infants (29 days to 1 year) (specify age range): Yes; ages 29 days to 1
year.
q. … Research Evidence
Research evidence should include a brief description of the evidence base for valid … Include results of all tests of validity and reliability, including description(s) of the study
sample
-
www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-229-fullreport.pdf
February 01, 2018 - Measure Description
Please provide a non-technical description of the measure that conveys what it measures … The results of a 9-year
retrospective study (Han, et al., 2003) indicated that 29 percent of infants … Population – infants (29 days to 1 year) (specify age range): Yes; ages 29 days to 1
year.
q. … Research Evidence
Research evidence should include a brief description of the evidence base for valid … Include results of all tests of validity and reliability, including description(s) of the study
sample
-
www.cahps.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-229-fullreport.pdf
February 01, 2018 - Measure Description
Please provide a non-technical description of the measure that conveys what it measures … The results of a 9-year
retrospective study (Han, et al., 2003) indicated that 29 percent of infants … Population – infants (29 days to 1 year) (specify age range): Yes; ages 29 days to 1
year.
q. … Research Evidence
Research evidence should include a brief description of the evidence base for valid … Include results of all tests of validity and reliability, including description(s) of the study
sample
-
ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-229-fullreport.pdf
February 01, 2018 - Measure Description
Please provide a non-technical description of the measure that conveys what it measures … The results of a 9-year
retrospective study (Han, et al., 2003) indicated that 29 percent of infants … Population – infants (29 days to 1 year) (specify age range): Yes; ages 29 days to 1
year.
q. … Research Evidence
Research evidence should include a brief description of the evidence base for valid … Include results of all tests of validity and reliability, including description(s) of the study
sample